Osteoarthritis Research Society International

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
Tuesday, September 12, 2023

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

Retrieved on: 
Monday, March 20, 2023

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, today announced pooled gait data from a world-renowned gait laboratory in Adelaide, Australia, which served as a study site for two studies of lead candidate XT-150 in patients with knee osteoarthritis (OA). XT-150 is a locally injectable plasmid DNA (pDNA)-delivered gene therapy expressing IL-10v, a proprietary modified version of interleukin-10 (IL-10), which Xalud is evaluating across a broad range of chronic inflammatory diseases in clinical and preclinical studies.

Key Points: 
  • The results demonstrate a positive signal supporting the use of XT-150 as a potential effective treatment in knee OA with the goal of improving joint function.
  • The data were presented in a poster presentation titled “Functional improvements in knee kinematics during walking gait over six months following treatment with XT-150: pooled results from two clinical trials” at the 2023 Osteoarthritis Research Society International (OARSI) World Congress.
  • We believe that this supplements the body’s own IL-10 activity and may restore immune system homeostasis in chronic inflammatory diseases such as knee OA.
  • Xalud has included gait analysis as part of its multi-study development program to provide functional assessment in addition to patient reported outcomes.

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17 Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

China Anti-Rheumatic Drug Market Forecasts Report 2022: A $24.65 Billion Market by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023

The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The market is projected to grow at a CAGR of 3.73% to attain a value of US$24.654 billion by 2027.
  • A growing number of patients suffering from arthritis in China is the major driver of the antirheumatic drugs market in the country.
  • As such, changing lifestyles will continue this trend during the next five years, thus positively impacting the market growth of antirheumatic drugs in China.

PAINWeek 2020 Welcomes Osteoarthritis Research Society International

Retrieved on: 
Wednesday, March 25, 2020

MONTCLAIR, N.J., March 25, 2020 /PRNewswire-PRWeb/ --PAINWeek is pleased to announce that the Osteoarthritis Research Society International (OARSI)for the first timewill present a full day track at the PAINWeek National Conference on Tuesday, September 9.

Key Points: 
  • MONTCLAIR, N.J., March 25, 2020 /PRNewswire-PRWeb/ --PAINWeek is pleased to announce that the Osteoarthritis Research Society International (OARSI)for the first timewill present a full day track at the PAINWeek National Conference on Tuesday, September 9.
  • The Osteoarthritis Research Society International (OARSI) is the leading medical society for advancing the understanding, early detection, treatment, and prevention of osteoarthritis (OA) through its exclusive dedication to research.
  • Debra Weiner, Executive Vice President, Program Development, remarked, "Given the emergence of new guidelines and therapeutic interventions for osteoarthritis, it is very timely and relevant for OARSI to be at PAINWeek 2020."
  • OARSI is very excited to start a new collaboration with PAINWeek and jointly highlight the exciting research and new treatment guidelines that are being developed.

Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences

Retrieved on: 
Monday, January 27, 2020

SAN DIEGO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced the positive results of multiple resiniferatoxin (RTX) pre-pivotal (phase 1b/2) clinical studies, which will be presented at two upcoming prestigious pain conferences.

Key Points: 
  • SAN DIEGO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced the positive results of multiple resiniferatoxin (RTX) pre-pivotal (phase 1b/2) clinical studies, which will be presented at two upcoming prestigious pain conferences.
  • An abstract has been accepted and clinical data for the RTX osteoarthritis pain trial will be presented at the upcoming Osteoarthritis Research Society meeting (OARSI) in May 2020.
  • A late breaking scientific abstract has been accepted and clinical data for the RTX cancer pain phase 1 clinical study will be presented at the upcoming American Academy of Pain Medicine in March 2020.
  • We look forward to discussing our clinical data in upcoming scientific conferences as we continue our fast-paced development programs."

Data from the MIV-711 Phase II Program to be Presented at the OARSI World Congress

Retrieved on: 
Tuesday, April 30, 2019

STOCKHOLM, April 30, 2019 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis Research Society International (OARSI) world congress, which will take place 2-5 May in Toronto, Canada.

Key Points: 
  • STOCKHOLM, April 30, 2019 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis Research Society International (OARSI) world congress, which will take place 2-5 May in Toronto, Canada.
  • Data from the six months' open label extension study of MIV-711 in patients with osteoarthritis will be presented.
  • The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.
  • Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership.